CCG1423, CAS NO.285986-88-1

ccg-1423 is a novel inhibitor of rhoa/c-mediated gene transcription that is capable of inhibiting invasion of pc-3 prostate cancer cells in a matrigel model of metastasis.
ic50 value: 1.5 um [1]
target: rho signaling inhibitor
in vitro: ccg-1423 selectively inhibited spontaneous pc-3 prostate cancer cell invasion through a matrigel matrix, but not the gαi-dependent lpa-stimulated skov-3 ovarian cancer cell invasion, in vitro. at 100 μm, nearly complete inhibition of invasion was achieved with a lesser degree of toxicity than that induced by ccg-1423 at 10 μm [1]. srf binds to this site in vivo and the srf inhibitor ccg-1423 completely blocks stars proximal reporter activity in h9c2 cells [3]. pharmacological mkl-inhibition with ccg-1423 significantly inhibited ccn1 promoter activity as well as mrna and protein expression[4].
in vivo: pharmacological srf inhibition by ccg-1423 reduced nuclear mkl1 and improved glucose uptake and tolerance in insulin-resistant mice in vivo [2].